N-Tertaining a New Signaling Paradigm for the Cardiomyocyte β 1 -Adrenergic Receptor

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Receptor Signaling

Background:

• Beta 1 -adrenergic receptors (β 1 ARs) are key mediators of catecholamine effects in heart cells.
• While acutely beneficial, chronic β 1 AR activation contributes to heart failure progression.
• Existing research assumes β 1 ARs function solely as full-length proteins.

Purpose of the Study:

• To investigate the role of different β 1 AR forms in cardiomyocyte signaling.
• To explore the signaling properties of N-terminally truncated β 1 ARs.
• To identify novel therapeutic targets for heart failure based on β 1 AR structure.

Main Methods:

• Detection and characterization of full-length and N-terminally truncated β 1 ARs in cardiomyocytes.
• Analysis of O-glycan modifications regulating β 1 AR N-terminal cleavage.
• Assessment of signaling pathways activated by truncated β 1 ARs, including protein kinase B activation and apoptosis resistance.

Main Results:

• β 1 ARs exist as both full-length and N-terminally truncated forms in cardiomyocytes.
• N-terminal cleavage is regulated by O-glycan modifications.
• Truncated β 1 ARs constitutively activate protein kinase B and protect against doxorubicin-induced apoptosis.

Conclusions:

• A novel signaling paradigm for β 1 ARs is identified, involving distinct functions of truncated forms.
• The β 1 AR N-terminus is a critical determinant of receptor signaling and responsiveness.
• Targeting β 1 AR N-terminal processing represents a potential therapeutic strategy for heart failure.